
## Khashayar Esfahani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8244611/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Moving towards personalized treatments of immune-related adverse events. Nature Reviews Clinical Oncology, 2020, 17, 504-515.	27.6	189
2	Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. New England Journal of Medicine, 2019, 380, 2375-2376.	27.0	162
3	Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. New England Journal of Medicine, 2017, 376, 1989-1991.	27.0	154
4	Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nature Communications, 2019, 10, 4712.	12.8	76
5	Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. New England Journal of Medicine, 2020, 382, 2374-2375.	27.0	54
6	The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers, 2018, 10, 204.	3.7	37
7	Adverse events associated with immune checkpoint inhibitor treatment for cancer. Cmaj, 2019, 191, E40-E46.	2.0	36
8	A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Frontiers in Oncology, 2014, 4, 174.	2.8	22
9	HSP90 as a novel molecular target in non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2016, 7, 11.	2.7	19
10	Acute Liver Failure Because of Chronic Lymphocytic Leukemia: Case Report and Review of the Literature. Current Oncology, 2011, 18, 39-42.	2.2	15
11	Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. PLoS ONE, 2016, 11, e0167906.	2.5	13
12	Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression. Journal of Oncology Practice, 2018, 14, 514-516.	2.5	13
13	A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer Journal of Clinical Oncology, 2020, 38, 3581-3581.	1.6	8
14	Erdheim-Chester Disease: The Importance of Information Integration. Case Reports in Oncology, 2017, 10, 613-619.	0.7	7
15	Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary. BMJ Case Reports, 2014, 2014, bcr2014204287-bcr2014204287.	0.5	6
16	A phase I open prospective cohort trial of curcumin plus tyrosine kinase inhibitors for EGFR-mutant advanced non-small cell lung cancer Journal of Clinical Oncology, 2019, 37, e20611-e20611.	1.6	6
17	Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy. BMJ Case Reports, 2016, 2016, bcr2016215525.	0.5	5
18	Programmed Cell Death Ligand 1–Induced Coma From Diffuse Cerebritis. Journal of Oncology Practice, 2018, 14, 134-135.	2.5	4

KHASHAYAR ESFAHANI

#	Article	IF	CITATIONS
19	Reply to â€~Personalized treatment of immune-related adverse events — balance is required'. Nature Reviews Clinical Oncology, 2020, 17, 518-518.	27.6	4
20	Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report. , 2021, 9, e001831.		4
21	Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis. , 2018, 6, 154.		3
22	Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy Journal of Clinical Oncology, 2019, 37, 9561-9561.	1.6	2
23	An unusual cause of STEMI and cardiac tamponade. BMJ Case Reports, 2014, 2014, bcr2014206926-bcr2014206926.	0.5	Ο
24	Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+ breast cancer Journal of Clinical Oncology, 2014, 32, e11585-e11585.	1.6	0